Loading the security page…
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Cytek Biosciences, Inc. (CTKB) is a company in the Health care sector; its shares trade on Nasdaq.
The price of Cytek Biosciences, Inc. (CTKB) on October 30, 2026 is 6.12 $, −2.78 % on the day. Over 52 weeks the stock traded between 3.31 $ and 6.21 $; the price now sits 97 % of the way up that range. Over the past year the price changed by +30.60 %. Market capitalization is 796.14 million $, rank 13 among 23 stocks of the same industry with a known capitalization.
Cytek Biosciences, Inc. trades on Nasdaq under the ticker CTKB. The company belongs to the Health care sector. The trading history on this page starts on 23 July 2021.
Over the past 52 weeks CTKB has traded between 3.31 $ and 6.21 $. As of 30 October 2026 the price stood 66.90 % of the way from the 52-week low to the high.
Over one year CTKB shares rose 30.60 %; over six months they rose 13.88 %. Volatility over 90 days is 48.75 %. Dividends are not included: this is price change only, as of 30 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 3.9, above the sector median of 3.6. Price to book is 2.5, above the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
Cytek Biosciences, Inc. reported revenue of 207M $ and a net loss of 81M $ over the last four quarters. Net margin is −38.98 %. Revenue changed by +5.44 % year over year. Earnings per share are −0.63 $. Market capitalisation is 796M $.
CTKB has a return on equity of −25.03 %, above the sector median of −40.58 %. Return on assets is −18.03 %, above the sector median of −30.08 %. Operating margin is −21.60 %, below the sector median of −20.96 %.